This book is a set of analyzes of the methods and practices used to manage the risks associated with OTC derivatives and their performance during the financial crisis 2007-8. It covers the areas of counterparty risk measurement, pricing (CVA), hedging, guarantees, stress testing, back testing, and integration into economic capital frameworks.

A group of experienced experts will discuss different ideas, trends and new models. The content of the book is more important in the light of the recent proposals of the Basel Committee on Banking Supervision for changes in regulatory capital to counterparty risk.

Contains useful information useful to practitioners, regulators, consultants, accountants, legislators, auditors and researchers to understand the core and technical issues often on the table. The book is a collection of clear and concise articles produced by some of the most experienced and most prominent specialists in this field.

Each of them sought to produce material that is objective and accessible. This provides a valuable set of ideas and tools to meet the changes and challenges ahead and address some of the most important issues right now: Proposed changes in counterparty risk capital may cause regulatory capital to credit risk to double banks will have to invest huge resources to update counterparty risk management systems Enhancement of methods and processes to address claims for faulty risk management, validation and restoration of the model, stress tests and risk control, and management of market risk to counterparty risk is essential under FAS 157, International Asph 39 The book consists of 14 chapters divided into four broad areas: * cover chapters 1 to 5 topics related to the measurement and management of risk corresponding parties.

It focuses on two new issues: counterparty risk and collateral system. * Chapters 6 to 10 cover topics related to pricing and hedging of counterparties and collateral arrangements.

CVAs have caused heavy losses to banks during the recent crisis and some of the Basel Committee's recent proposals to reform regulatory capital have stimulated counterparty risk. The effects of guarantees on the valuation of OTC derivatives, financing costs and funding availability are considered important current issues that are covered.

* Chapters 11 and 12 cover stress testing for counterparty risk. Recent experience has shown that stress testing frameworks need to be expanded and strengthened and that some new and promising ideas are described.

* Chapters 13 and 14 cover the posterior testing of counterparty exposure models and the integration of counterparty risk into economic and regulatory capital frameworks.

I want that book.